Common shares, Euro 0.12 nominal value per share

LAVA THERAPEUTICS N.V.

Yalelaan 62, Utrecht, P7, 3584 CM

This Statement is being filed by Cooperatieve Gilde Healthcare IV U.A. ("Gilde Healthcare"), Gilde Healthcare IV Management B.V. ("GHCIVM"), Gilde Healthcare Holding B.V. ("GHH", and together with Gilde Healthcare and GHCIVM, the "Reporting Entities"); the managing directors of GHH: Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director) (together, the "Managing Directors"). The Reporting Entities and Managing Directors are collectively referred to as the "Reporting Persons." The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached hereto as Exhibit 99.2. Each Reporting Person disclaims beneficial ownership of all securities reported in this Schedule except to the extent of such Reporting Person's pecuniary interest therein, other than those securities reported herein as being held directly by such Reporting Person.

The business address of the principal offices of each Reporting Person is Stadsplateau 36 P7, 3521 AZ Utrecht, The Netherlands.

GHCIVM manages and advises Gilde Healthcare and is owned by GHH. Gilde Healthcare makes venture capital investments in companies developing biotechnology, molecular diagnostics and medical technology products.

None of the Reporting Persons are, nor during the last five years have been, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

GHCIVM, GHH, Manapouri B.V. and Martemanshurk B.V. are limited liability companies organized under Dutch law. Gilde Healthcare is a private equity investment fund organized under Dutch law.

According to the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on August 13, 2025, there were 26,305,295 Common Shares outstanding as of August 8, 2025. Gilde Healthcare is the record holder of an aggregate of 5,246,492 Common Shares, which represents beneficial ownership of approximately 19.9% of the outstanding Common Shares as of August 8, 2025. GHCIVM, as the manager of Gilde Healthcare, has the power to vote and dispose of securities held by Gilde Healthcare and may be deemed to beneficially own the securities held of record by Gilde Healthcare. As a result, each of the Reporting Persons may beneficially own 5,246,492 Common Shares, or approximately 19.9% of the outstanding Common Shares.

Each Reporting Person has shared power to vote and dispose of 5,246,492 Common Shares.

On October 8, 2025, Gilde Healthcare sold 28,954 Common Shares at a weighted average price per share of $1.5727 for aggregate proceeds of approximately $45,535.96. On October 9, 2025, Gilde Healthcare sold 48,169 Common Shares at a weighted average price per share of $1.5568 for aggregate proceeds of approximately $74,989.50. On October 10, 2025, Gilde Healthcare sold 49,869 Common Shares at a weighted average price per share of $1.5474 for aggregate proceeds of approximately $77,167.29. On October 13, 2025, Gilde Healthcare sold 47,686 Common Shares at a weighted average price per share of $1.5377 for aggregate proceeds of approximately $73,326.76.